A Clinical Trial of D1+ Versus D2 Distal Gastrectomy for Stage IB & II Advanced Gastric Cancer

Inclusion Criteria : * Histologically proven primary gastric adenocarcinoma * T1N1, T2N0, T2N1, T3N0, T3N1 by CT scan (AJCC 7th classification) and intraoperative surgical staging prior to resectional procedure * Location of primary tumor; antrum, or angle, lower body or mid body of the stomach * No evidence of other distant metastasis * Aged ≥ 20 year old * Performance status (PS) of 0 or 1 on Eastern Cooperative Oncology Group (ECOG) scale * No prior treatment of chemotherapy or radiation therapy against any other malignancies, and no prior treatment for gastric cancer including endoscopic mucosal resection * Adequate organ functions defined as indicated below: * WBC 3000/mm3 - 12,000/mm3 * \>serum Hemoglobin 8.0 g/dl * \> serum Platelet 100 000/mm3 * \< serum AST 100 IU/l * \<serum ALT 100 IU/l * \< Total Bilirubin 2.0 mg/dl * Written signed informed consent Exclusion Criteria : * Active double cancer (synchronous double cancer and metachronous double cancer within five disease-free years), excluding carcinoma in situ (lesions equal to intraepithelial or intramucosal cancer) * Gastric remnant cancer * ≥T4a in surgical staging before resection * N2 or more (number of metastatic lymph nodes ≥3) in CT scan * Histologically rare variants in WHO Classification such as Adenosquamous, Hepatoid, Squamous cell, Undifferentiated, , neuroendocrine carcinoma and others * Pregnant or breast-feeding women * Mental disorder(diagnosed with mental disorder on medical record) * systemic administration of corticosteroids(include Herbal Medication) * unstable angina or myocardial infarction within 6 months of the trial * unstable hypertension * severe respiratory disease requiring continuous oxygen therapy * previous upper abdominal surgery except laparoscopic cholecystectomy